Members of BioNumerik’s Board of Directors are Frederick H. Hausheer, M.D.; James R. Leininger, M.D.; Dennert O. Ware; and John W. Yarbro, M.D., Ph.D. The following are brief biographies of our external Directors.
has served as a member of our Board of Directors since February 1993. Dr. Leininger is Chairman Emeritus and a member of the board of directors of Kinetic Concepts, Inc., a specialized hospital and intensive care medical equipment manufacturer. Dr. Leininger founded Kinetic Concepts and served as its Chairman of the Board from 1976 until 1997. He has been a private investor since 1997. From January 1990 to November 1994, Dr. Leininger served as President and Chief Executive Officer of Kinetic Concepts. From 1975 until October 1986, Dr. Leininger was a co-director of the Emergency Departments of the Baptist Hospital System in San Antonio. Dr. Leininger was a founding investor in Renal Care Group, a publicly traded renal dialysis company that was acquired by Fresenius Medical Care. He also founded a radiology imaging company, National Imaging Affiliates, which was sold to HealthSouth Corporation. He has founded or invested in many other early stage corporations. Dr. Leininger serves on a number of boards of private companies, charitable foundations and one college. Dr. Leininger received a B.A. from Indiana University and an M.D. from Indiana University School of Medicine.
has served as a member of our Board of Directors since October 2007. From April 2000 to November 2006, Mr. Ware served as CEO of Kinetic Concepts, Inc. (“KCI”), a San Antonio-based global medical technology company. Before joining KCI, Mr. Ware served as President and CEO of Boehringer Mannheim Corporation, a market leader in medical diagnostic equipment. Mr. Ware was named the 2005 Medical Device CEO of the Year by leading industry analyst firm Frost & Sullivan in recognition of his leadership, vision, and impact on KCI’s growth and performance. In addition, he was selected as a recipient of the Ernst & Young Entrepreneur of the Year award in 2006. Mr. Ware received a BSChE from Purdue University and an MBA from Indiana University.
has served as a member of our Board of Directors since June 1997. Dr. Yarbro is the Founding Editor and Editor Emeritus of Seminars in Oncology, Emeritus Professor of Medicine and a past Chairman of the Department of Oncology of the University of Missouri School of Medicine. Dr. Yarbro retired as Professor of Medicine in 1993 and has been an editor, writer, consultant, and private investor since that time. Dr. Yarbro served two terms as the Chairman of the Panel on Hematologic & Neoplastic Disease and as a Member of the Committee of Revision of the U.S. Pharmacopeia. Dr. Yarbro also served as Vice-Chairman of the American Joint Committee on Cancer, and during his career he has held numerous senior and internationally recognized leadership, administrative and advisory positions with organizations including the American Cancer Society and the American Society of Clinical Oncology. Dr. Yarbro has also served as Associate Director of the National Cancer Institute and a Fulbright Lecturer. Dr. Yarbro received a B.S., summa cum laude, an M.D. degree from the University of Louisville and a Ph.D. in biochemistry from the University of Minnesota.
Our scientific advisors are leading clinicians and researchers from major medical and academic centers in the United States and Europe. The members of our Scientific Advisory Board provide us with scientific and medical advice, review our development progress, and assess new technologies relevant to our discovery and development efforts.
The following individuals serve as members of our Scientific Advisory Board:
Director, The Sidney Kimmel Comprehensive Center at Johns Hopkins and Professor of Oncology and Medicine, The Johns Hopkins Hospitals; President of the American Society of Clinical Oncology (1991); Former Chairman, FDA Oncology Drug Advisory Committee.
Associate Director, The Sidney Kimmel Comprehensive Center at Johns Hopkins; Director of Tumor Biology Laboratory; Professor of Oncology and Medicine, The Johns Hopkins University and School of Medicine.
Professor of Organic Chemistry, North Carolina State University; Minerva Award Recipient, SUNY-Potsdam, 1997; Japan Society for the Promotion of Science Fellow, 1998; Associate Editor, Journal of Organic Chemistry
Director of Medical Oncology, The Sidney Kimmel Comprehensive Center at Johns Hopkins, and Professor of Oncology and Medicine, The Johns Hopkins University School of Medicine; Member, U.S. Pharmacopeia Drug Advisory Panel for Hematologic and Neoplastic Disease.
Former FDA Oncology Pharmacology and Toxicology Reviewer; Professor of Pharmacology, the University of South Alabama.
Director, Hematology/Medical Oncology, Ellis Fischel Cancer Center; Professor of Medicine and Oncology, University of Missouri-Columbia; FDA Oncology Drug Advisory Committee.
Head of Department of Medical Oncology and Professor of Medical Oncology, Free University Hospital (The Netherlands); Head of the European Organization for the Research and Treatment of Cancer (EORTC); Former President of the European Society of Medical Oncology (ESMO).
Senior Vice President for Scientific Affairs at Grace Cancer Drug Center, Roswell Park Cancer Institute.
Professor of Medicine, Emory University School of Medicine; Senior Associate Director, The Winship Cancer Institute of Emory University; Associate Medical Director, Emory Hospitals
Associate Dean for Clinical Research, University of Chicago Cancer Research Center; Chairman, Cancer & Leukemia Group B; Former Chairman, FDA Oncology Drug Advisory Committee; President, the American Society of Clinical Oncology.
